 |
SynOx Therapeutics
Last updated: July 23, 2024
Nick La Thangue, CEO
Ireland | Funding: $153.9M (+)
Website: https://synoxtherapeutics.com/
SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue.
Website: https://synoxtherapeutics.com/
SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue.
